α1-antitrypsin deficiency (AATD) remains the only readily identified genetic cause of chronic obstructive pulmonary disease (COPD). Furthermore, there is growing evidence that even a moderate deficiency increases the risk of lung disease among smokers. Despite these facts, the uptake of testing for AATD in at-risk populations remains low for many reasons, and a lack of clarity among clinicians regarding the most appropriate diagnostic techniques presents a major deterrent.
This 2019 guide for α1-antitrypsin deficiency testing addresses the benefits of A1AT diagnosis, the technical basis of the available diagnostic methods. A1AT phenotyping by isolectric focusing is part of the available diagnostic methods and it allows detection of multiple variants of A1AT in one assay.
The topics covered should equip clinicians with the core knowledge required to confidently assess patients for AATD and increase the number of AATD testing.
Test associated with this resource
Related instrument
コンパクトかつ導入しやすい全自動キャピラリー電気泳動システム
進化が違いを生む
Sebiaの専門知識を結集した高スループット装置。
Discover more resources on Alpha-1 Antitrypsin Deficiency
このセクションには広く一般に公開されることを目的とした情報が含まれており、そのため、お住まいの国では入手できない、または有効でない製品の詳細や情報が含まれている可能性があります。お近くのSebia担当者にお問い合わせください。医療従事者向けの情報です。試薬の添付文書および機器の取扱説明書の指示を注意深くお読みください。